EXHIBIT 99.1
Contact: Steven Koehler Michael Mitchell
Chief Financial Officer Director of Corporate Communications
The Medicines Company The Medicines Company
(973) 656-1616 (973) 656-1616
investor.relations@themedco.com
For Immediate Release
THE MEDICINES COMPANY REPORTS SECOND QUARTER 2002
FINANCIAL RESULTS AND CONFIRMS ANNUAL GUIDANCE
PARSIPPANY, NJ, July 23, 2002 - The Medicines Company (NASDAQ: MDCO) announced
today its results for the quarter ended June 30, 2002. The Company is confirming
its year-end 2002 ANGIOMAX(R) net revenue goal of $36-$41 million.
Highlights for the quarter included:
* Net revenue increased to $7.2 million, compared to $2.0 million for
the second quarter 2001, primarily generated by sales of the company's
flagship product, ANGIOMAX. For the first half of 2002, net revenue
was $14.9 million, compared to $3.9 million for the same period in
2001.
* Second quarter 2002 net revenue was impacted by a $1.1 million order
that was not received by the customer until the first week in July.
Because the product was received in the third quarter, the $1.1
million in revenue will be recorded in the third quarter.
* Net loss attributable to common stockholders decreased to $13.1
million, compared to $16.0 million for the second quarter 2001. For
the first half of 2002, net loss was $24.8 million, compared to $35.1
million for the same period in 2001.
* A completed public offering of common stock resulted in net proceeds
to MDCO of $31.0 million. As of June 30, 2002 the Company had cash,
cash equivalents, available for sale securities and accrued interest
receivable of $64.2 million.
* REPLACE-2 clinical trial continues to enroll patients as planned, with
greater than 4,800 of the 6,000 patients enrolled to-date.
* Two publications in the journal Anesthesiology regarding clevidipine,
the Company's potential acute hypertension product.
Dave Stack, President and CEO of The Medicines Company stated, "The reported net
revenue figure was reduced by the effect of a $1.1 million shipment in June that
we had expected to report in the second quarter,
but have recorded instead in the third quarter. Therefore, ANGIOMAX sales
to-date are in line with our expectations, in the center of our anticipated
range."
There will be a conference call with management today at 5:00 p.m. Eastern Time
to discuss these results. To listen in, please dial 800-472-8325 and request The
Medicines Company 2002 Second Quarter conference call. If you are calling from
outside of the United States, please dial 1-706-679-0816. If you cannot attend
the live call, a digital replay will be available through August 6. Please call
800-642-1687 in the U.S. or 1-706-645-9291 internationally and enter passcode
4892130. Additionally, this call is being webcast by CCBN and can be accessed at
The Medicines Company's web site (www.themedicinescompany.com).
The Medicines Company was founded in 1996 to acquire, develop and commercialize
selected pharmaceutical products in late stages of development and approved
products. ANGIOMAX is approved in the United States for use as an intravenous
anticoagulant in combination with aspirin in patients with unstable angina
undergoing coronary balloon angioplasty, and is expected to be the cornerstone
product of a planned acute-care hospital franchise. The Company is also
developing another intravenous agent, clevidipine, for the short-term control of
high blood pressure in the hospital setting.
This press release contains forward-looking statements that involve a number of
risks and uncertainties. For this purpose, any statements contained herein that
are not statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words, "believes,"
"anticipates," "plans," "expects," "intends," and similar expressions are
intended to identify forward-looking statements. Important factors that could
cause actual results to differ materially from the expectations described in
these forward-looking statements are set forth under the caption "Risk Factors"
in the Company's Current Report on Form 8-K filed with the Securities and
Exchange Commission on June 25, 2002 and incorporated herein by reference. These
risk factors include risks as to the commercial success of ANGIOMAX; how long
the Company will be able to operate on its existing capital resources; whether
the Company's products (other than ANGIOMAX for its approved indication) will
advance in the clinical trials process, the timing of such clinical trials,
whether the clinical trial results will warrant continued product development,
whether and when, if at all, the Company's products will receive approval from
the U.S. Food and Drug Administration or equivalent regulatory agencies, and for
which indications, and, if such products receive approval, whether they will be
successfully marketed; the Company's history of net losses; and the Company's
dependence on third parties, including manufacturers, suppliers and
collaborators. We do not assume any obligation to update any forward-looking
statements.
THE MEDICINES COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
UNAUDITED
THREE MONTHS ENDED JUNE 30,
----------------------------
2002 2001
------------ ------------
Net revenue $ 7,156,130 $ 2,047,541
Operating Expenses
Cost of revenue 1,647,141 319,043
Research and development 9,392,052 8,308,956
Selling, general and administrative 9,400,051 9,567,941
------------ ------------
Total operating expenses 20,439,244 18,195,940
Loss from operations (13,283,114) (16,148,399)
Interest income, net 142,031 995,270
------------ ------------
Loss on sale of investments -- (850,000)
------------ ------------
Net loss (13,141,083) (16,003,129)
Dividends and accretion to redemption
value of redeemable preferred stock -- --
------------ ------------
Net loss attributable to common stockholders $(13,141,083) $(16,003,129)
============ ============
Basic and diluted net loss attributable to
common stockholders per common share $ (0.37) $ (0.49)
============ ============
Shares used in computing net loss attributable
to common stockholders per common share:
Basic and diluted 35,390,977 32,357,360
============ ============
SIX MONTHS ENDED JUNE 30,
----------------------------
2002 2001
------------ ------------
Net revenue $ 14,871,031 $ 3,908,829
Operating Expenses
Cost of revenue 2,732,630 651,443
Research and development 18,701,124 20,904,153
Selling, general and administrative 18,731,888 18,626,877
------------ ------------
Total operating expenses 40,165,642 40,182,473
Loss from operations (25,294,611) (36,273,644)
Interest income, net 512,222 2,064,529
Loss on sale of investments -- (850,000)
------------ ------------
Net loss (24,782,389) (35,059,115)
Dividends and accretion to redemption
value of redeemable preferred stock -- --
------------ ------------
Net loss attributable to common stockholders $(24,782,389) $(35,059,115)
============ ============
Basic and diluted net loss attributable to common
stockholders per common share $ (0.71) $ (1.12)
============ ============
Shares used in computing net loss attributable to
common stockholders per common share:
Basic and diluted 35,010,909 31,309,946
============ ============
THE MEDICINES COMPANY
CONDENSED CONSOLIDATED BALANCE SHEETS
UNAUDITED JUNE 30, DECEMBER 31,
2002 2001
----------- ------------
ASSETS
Cash, cash equivalents, available for sale securities $64,112,559 $54,009,376
Accrued interest receivable 87,681 6,757
Accounts receivable, net 5,312,556 5,346,684
Inventories 18,761,792 16,610,928
Fixed assets, net 989,864 1,223,528
Other assets 954,826 703,640
----------- -----------
Total assets $90,219,278 $77,900,913
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities $17,570,799 $16,779,949
Deferred revenue 1,458,333 --
Stockholders' equity 71,190,146 61,120,964
----------- -----------
Total liabilities and stockholders' equity $90,219,278 $77,900,913
=========== ===========